ADC Contract Manufacturing Market Size Worth over USD 6.8 Billion in 2035 | Roots Analysis

The growth in the ADC contract manufacturing market size over the next decade is likely to be the result of a rise in the demand for antibody drug conjugates. The manufacturing of ADC therapeutics requires specialized techniques for the manufacture of ADC process components including antibody, HPAPI / cytotoxic payload and linker. 

Further, manufacturers require access to state-of-the-art linker technologies and must possess the ability to carry out the bioconjugation of the antibody to the cytotoxic drug. This is indicative of the fact that ADC manufacturing process is complex and requires different manufacturing platforms and process technologies.

According to Roots Analysis, the ADC contract manufacturing market is anticipated to be worth USD 1.79 billion in 2024, and this value is likely to reach USD 6.8 billion by 2035, expanding at a CAGR of 13%.

Key Report Takeaways 

§  The majority of the large contract manufacturers (50%) offer a wide range of ADC manufacturing services across all scales of operation; more than 45% of the ADC conjugation facilities are based in North America

§  A comprehensive set of company profiles of prominent / emerging players, offer valuable insights into their current strategic focus areas and future initiatives, empowering stakeholders with crucial information

§  75% of the manufacturing agreements inked in this domain were focused on clinical and commercial manufacturing of ADCs, across different geographical regions

§  Driven by the expanding pipeline of ADC therapeutics and manufacturing expertise available with contract service providers, the ADC contract manufacturing market is poised to witness significant growth in the future

§  The current and projected future market is anticipated to be well distributed across various target indications, antibody generations and antibody origins

§  With the rise in demand for ADC therapeutics, the opportunity for ADC components including antibody, payload and linker is estimated to increase significantly during the forecast period

Competitive Landscape of ADC Contract Manufacturing Market

The ADC contract manufacturing market landscape features the presence of 30 ADC contract manufacturers. Over 45% of the CMOs were established before 2000, demonstrating extensive experience and expertise in the contract manufacturing industry. It is worth highlighting that 50% of the ADC contract manufacturers are based in North America. 

Within Europe, Switzerland emerged as the hub of ADC contract manufacturers. Notably, 43% of the companies offer all types of manufacturing services related to ADCs. Moreover, industry stakeholders are actively undertaking expansion initiatives for their product / service portfolios to become one-stop shops for mitigating the challenges associated with technology transfer and scale-up. Examples of companies established before 1980 (in alphabetical order) include Lonza, MilliporeSigma, Sartorius and Sterling Pharma Solutions.

ADC Contract Manufacturing Market Regional Outlook

Based on the key geographical regions, the ADC contract manufacturing market can be segmented into three major regions, North America, Europe and Asia-Pacific and rest of the world. Led by the US, North America is anticipated to capture the majority share of the ADC contract manufacturing market in 2024 and this trend is likely to remain unchanged in the forecasted timeframe. 

Key industry players such as AbbVie Contract Manufacturing, Abzena, GBI and Piramal Pharma Solutions are pivotal in shaping the market dynamics in this region. Additionally, the rising demand for ADC therapeutics in Europe is likely to be the reason for an increase in the contract manufacturing market for ADCs in the region.

Asia-Pacific is likely to exhibit lucrative opportunities owing to increasing prevalence of cancer cases. The emergence of several ADC contract Manufacturers in the area is one factor, promising growth not only in the emerging economies of Asia-Pacific, but also in the countries in rest of the world.

ADC Contract Manufacturing Market Key Players

Examples of key companies engaged in ADC contract manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie Contract Manufacturing, Abzena, CARBOGEN AMCIS, Catalent Pharma Solutions, Cerbios-Pharma, Formosa Laboratories, GBI, Lonza, MabPlex, Millipore Sigma, Piramal Pharma Solutions, Sterling Pharma Solutions, WuXi Biologics.

It is interesting to note that in September 2023, WuXi Biologics inked a strategic deal with Mabwell Therapeutics to support and accelerate Mabwell’s ADC research, development and commercialization initiatives. Such types of agreements are expected to drive the demand for antibody drug conjugates across the globe, resulting in substantial market growth during the forecast period.

ADC Contract Manufacturing Market Segments

Based on the research, Roots Analysis has segmented the ADC Contract Manufacturing Market into Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Antibody Isotype, Type of Payload, Type of Linker and Key Geographical Regions.

by Stage of Development

§  Phase I

§  Phase II

§  Phase III

§  Commercial

by Process Component

§  Antibody

§  HPAPI / Cytotoxic Payload

§  Conjugation / Linker

§  Fill / Finish

by Target Indication

§  Solid Tumors

§  Hematological Tumors

§  Others

by Antibody Generation

§  Second Generation

§  Third Generation

§  Fourth Generation

§  Next Generation

by Antibody Origin

§  Human

§  Chimeric

§  Murine

§  Others

by Antibody Isotype

§  IgG1

§  IgG4

§  Others

by Type of Payload

§  Auristatin

§  Camptothecin

§  DNA Topoisomerase I Inhibitor

§  Maytansinoid

§  Others

by Type of Linker

§  Maleimide

§  SMCC

§  Tetrapeptide-based linker

§  Valine-citrulline

§  Others

by Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific and Rest of the World

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact US

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

Website: https://www.rootsanalysis.com